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Introduction
Anti-tumor therapies cause both apoptosis and senescence. We previously reported that an aurora kinase A inhibitor reduces melanoma growth through inducing senescence in vitro and in vivo (1) . The role of cellular senescence in restricting tumorigenesis upon oncogenic activation or tumor suppressor loss has been established (2) (3) (4) . Spontaneous induction of senescence is an initial defense against unrestrained proliferation. Expression of an oncogene in pre-malignant cells without loss of a tumor suppressor often results in oncogene-induced senescence (OIS). However, through a series of changes, pre-malignant cells can by-pass senescence, undergo transformation and become tumor cells (5) . When tumor cells are treated with cytostatic or cytotoxic drugs, they can be forced into another state of senescence, therapy-induced senescence (TIS). In vitro and in vivo data suggest that low doses of conventional anticancer compounds or gamma-radiation can trigger TIS (6) . A mouse lymphoma model demonstrates that TIS can result in improved animal survival (7) , which is of clinical interest. More than 20 anti-cancer reagents had been reported to induce senescence, resulting in stable cell cycle arrest and inhibition of tumor growth (8) .
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Author Manuscript Published OnlineFirst on July 7, 2015; DOI: 10.1158/1078-0432.CCR- Alisertib (MLN8237), an Aurora Kinase A (AURKA) inhibitor, blocks the G2 to M cell cycle progression, induces polyploidy, causes DNA damage, and results in senescence (1, (9) (10) (11) . MLN8237 is currently in clinical trials in liquid and solid tumors (12) (13) (14) . We have recently shown in preclinical mouse models that combining MLN8237 with an MDM2 antagonist will activate p53-mediated apoptosis and markedly enhance the therapeutic response of p53 wild-type tumors to MLN8237 (15) .
In an effort to identify a therapeutic regime of combined therapies that would result in the killing of both p53 mutant and p53 wild type tumor cells, we sought to evaluate of the efficacy of combining MLN8237 with agents that activate death receptors. Death receptor 5 (DR5) agonist antibodies are currently in clinical trials, but often exhibit a limited therapeutic index alone. Our in vitro studies showed that the death receptor ligand, Apo2L/TRAIL, demonstrated increased efficiency in killing of TIS tumor cells, as compared to non-senescent tumor cells, in a p53-independent manner. Moreover, a DR5 agonist antibody triggered marked apoptosis in tumor cells undergoing TIS induced by MLN8237 treatment. This combination therapy caused tumor regression in mouse xenograft and patient derived xenograft tumor models. These data suggest that combining alisertib with a DR5 agonist antibody may be highly effective for cancer therapy, and the response will be independent of p53 status.
Materials and Methods
Cell lines, tissue culture and chemical reagents: A375, Hs294T, SK-Mel-2 and SK-Mel-28 melanoma cells were purchased from American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM/F12 media supplemented with 10% FBS. All the cell lines were meticulously passaged and tested for mycoplasma monthly. The p53 inhibitor pifithrin-α (PTF-α) was obtained from Tocris Bioscience (#9502), anti-DcR1 (#4756), anti-BIM (#2933), anti-BAX (#2772), anti-Survivin (#2808), anti-p53 (#2524) antibodies were from Cell Signaling. Anti-FLIP (06-697) antibody was from Upstate (Lake Placid, NY).
Anti-OPG (500-P149) was from PEPROTECH (Rocky Hill, NJ). Anti-DcR2 (TA305975) was from ORIGENE (Rockville, MD). Anti-DR5 (NB100-56618) was from Imgenex (Littleton, CO) Cell viability assay: Cells were trypsinized and treated with trypan blue. The viable cells that excluded trypan blue were counted using a haemocytometer. (18) (19) (20) . Here we performed quantitative real-time PCR to determine the mRNA expression levels of more markers for senescence after treatment with 1µM MLN8237, which is comparable to the plasma concentration of MLN8237 in mice (15, 21) . We evaluated DEC1 (deleted in esophageal cancer 1), GLB1 (β-galactosidase1), CCNA2 (CyclinA2), CDKN1A (p21), CDKN2A (p16), IL-8, IL-6, and CXCL1 in two p53 WT and a death receptor ligand, Apo2L/TRAIL (25 ng/ml) simultaneously for five days. We observed that MLN8237 induced senescence (Fig. 1A ) and the combination treatment significantly reduced tumor cell viability compared to single treatment (Fig. 1B) . In addition, other aurora kinase inhibitors, such as aurora kinase B inhibitor, AZD1152, and pan-aurora kinase inhibitor, VX-680, also induced senescence in melanoma cells (Fig. S1B ) and reduced cell viability when combined with Apo2L/TRAIL (Fig. S1C ).
To determine whether p53 activation is required for this effect, we analyzed p53 after combined Apo2L/TRAIL treatment (Fig. 2B) . It was noted that MLN8237 stabilized the cleaved products of caspase-8 (p43/41 and p18) in both cell lines, which may augment apoptosis stimulation by Apo2L/TRAIL treatment (22) . This conclusion is supported by the loss of cell death when a pan-caspase inhibitor (10 µM) or caspase-8 inhibitor (10 µM) was added ( Fig. 2C and 2D ). The caspase-9 inhibitor (10 µM) partially rescued Apo2L/TRAIL-induced cell death ( Fig. 2C and 2D ), indicating that both intrinsic and extrinsic apoptotic pathways were involved. (Fig. 3A) . In addition, melanoma patient derived tumor tissues previously treated with MLN8237 in mice (1) also exhibited increased membrane presented DR5 (Fig. 3B) . In contrast, senescence reduced decoy receptor 2 (DcR2) and Osteoprotegerin (OPG) in Hs294T cells (Fig.   3C ). The expression of decoy receptors was cell line specific. While Hs294T cells did not express decoy receptor 1 (DcR1) and SK-Mel-28 cells did not express DcR2 or OPG (data not shown), the latter cell line had decreased levels of DcR1 when senescence was induced (Fig. 3C) . When the levels of DR5 in senescent tumor cells were knocked-down by siRNAs (Fig. 3D) , in response to Apo2L/TRAIL treatment, cell death was partially lost (Fig. 3E) . Similarly, when soluble OPG, which was secreted to culture supernatants to neutralize Apo2L/TRAL, was added to culture media, Apo2L/TRAIL-induced cell death was also partially lost (Fig. 3F) . These results indicate that the MLN8127-induced changes in display of death receptor and decoy receptors sensitize senescent tumor cells to Apo2L/TRAIL treatment by upregulating the DR5 death receptor and down regulating decoy receptors. (Fig. 4D ). These data suggest that activation of both intrinsic and extrinsic apoptotic pathways contribute to the Apo2L/TRAIL-induced apoptosis in senescent tumor cells.
DR5 agonist antibody activates apoptosis in TIS tumor cells in vitro and causes tumor regression in
pre-clinical mouse models in vivo. In contrast to Apo2L/TRAIL, which has relatively a short half-live in vivo, DR5 agonist antibody has a half-life of several days in vivo. When Hs294T cells treated with MLN8237 combined with increasing concentrations of DR5 agonist antibody (0-750 ng/ml) there was a dose dependent loss of cell viability based upon cell staining (Fig. 5A) . When viable cells were counted after treatment with DR5 antibody alone versus increasing concentrations of DR5 antibody plus MLN8237, the reduction in cell number was greater in MLN8237 induced senescent cells than in vehicle treated non-senescent tumor cells (Fig. 5A) . The combination of a DR5 agonist antibody with MLN8237 also reduced cell viability in other three melanoma cells (Fig. 5B) (Fig. 5C ). Pan-caspase inhibitor or caspase 8 inhibitor blocked DR5 agonist antibody-induced cell death (Fig. 5D) , suggesting that caspase-dependent apoptosis contributed to the loss of cell viability with treatment. In addition, a DR5 small-molecule activator (23) also produced dose dependent killing effects (0-15 µM) on MLN8237 treated senescent tumor cells ( Fig.   5E and S3A) and only effected the cells not co-treated with MLN8237 at the highest dose (15 µM). These results indicate that DR5 agonist antibody will be highly effective for in vivo studies. (Fig. 6A) . In addition, a patient derived xenograft from a melanoma patient, who had progressed after BRAF inhibitor treatment, revealed that treatment with DR5 antibody alone did not inhibit tumor growth, MLN8237 alone did significantly inhibit tumor growth, but the combined treatment with DR5 antibody and MLN8237 prevented tumor growth (Fig. 6B) .
To evaluate the effects of DR5 antibody and MLN8237 treatment in vivo at the cellular level, histological analysis of paraffin embedded PDX tumors was performed using special stains. SA-β-Gal staining showed that MLN8237 strongly induced tumor cell senescence in vivo (Fig. S3B) . Ki67 staining of tumors showed that MLN8237 treatment alone significantly blocked cell proliferation, while DR5 agonist antibody treatment alone did not significantly reduce cell proliferation and combined treatment with MLN8237 and DR5 agonist antibody did not further reduce the number of Ki67 positive cells over that of the MLN8237 treatment alone (Fig. 6C) 
the combined treatment with MLN8237 and DR5 antibody triggered significantly more apoptosis in vivo (Fig. 6D) . Thus the combination treatment resulted in a significant reduction in Ki67 staining (p<0.0001) and enhanced cleaved caspase-3 (p<0.0001). To determine whether the senescent cells are indeed undergoing apoptosis, we co-stained GLB1 with cleaved caspase 3 using tissue slides from the patient derived xenograft animal study. We found co-localization of GLB1 and cleaved caspase 3 (Fig. S4) . We can see overexpression in the senescent tumor tissues and co-localization of GLB1 and cleaved caspase 3.
Overall, our results show that combined treatment with a DR5 agonist antibody and MLN8237 blocked tumor growth through inducing senescence with a resultant reduction in cell proliferation (Ki67 staining p<0.0001) followed by a triggering apoptosis (cleaved caspase-3 p,0.0001), with the ultimate benefit of tumor regression.
Discussion
The effects of senescent cells on tumor growth remain controversial as the senescence-associated secretory phenotype (SASP) is characterized by secretion of many inflammatory cytokines and chemokines, which may induce a local or systemic pro-or anti-tumor reaction (8) , (24) (25) (26) (27) . Some studies Apo2L/TRAIL is a potential cancer therapeutic because it induces apoptosis specifically in most tumor tissues, but not in most normal tissues (42) . Preclinical and clinical studies indicate that recombinant human Apo2L/TRAIL is safe for potential therapeutic use (43, 44) . However, Apo2L/TRAIL has a very short half-life in vivo (45) . To overcome the short half-life of Apo2L/TRAIL, several specific death receptor agonist antibodies which have a long half-life were developed (46) . In vitro and in vivo data suggest that administration of DR5 agonist antibody decreases tumor cell proliferation and triggers tumor cell apoptosis in several different types of human cancer (47,48). Phase I clinical trials demonstrate that DR5 antibody is well tolerated (49). Our in vitro data suggest both a DR5 agonist antibody and a DR5 small-molecule activator can promote cell death in senescent tumor cells.
Our data in melanoma confirm these prior reports that DR5 agonist antibody can inhibit cell growth and trigger apoptosis (44, 45) , though the DR5 agonist antibody alone only reduced melanoma tumor viability by ~20-40%. A potential limitation of Apo2L/TRAIL or DR5 agonist therapy for cancers, including melanoma, is that many types of human cancer have lost sensitivity to Apo2L/TRAIL (50). While overcoming Apo2L/TRAIL resistance still remains a challenge, our in vitro data suggest that induction of senescence increased the sensitivity to Apo2L/TRAIL. A potential mechanism is that induction of senescence stabilized cleaved caspapse-8 products in response to Apo2L/TRAIL treatment. 
